<div id="readability-page-1"><p>Shares of Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) have been assigned a consensus rating of &#34;Buy&#34; from the seven brokerages that are currently  covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating.  The average 1-year target price among analysts that have covered the stock in the last year is $53.7143.</p><div><p><span></span><span>Get <strong>Royalty Pharma</strong> alerts:</span></p></div><ul><li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li></ul><p>A number of analysts have recently commented on the stock. Weiss Ratings raised shares of Royalty Pharma from a &#34;buy (b-)&#34; rating to a &#34;buy (b)&#34; rating in a report on Friday, May 1st. Morgan Stanley raised their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, April 10th. Citigroup lifted their target price on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of Royalty Pharma from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, May 9th. Finally, The Goldman Sachs Group  reissued a &#34;buy&#34; rating on shares of Royalty Pharma in a report on Thursday, February 12th.</p><p><b>Read Our Latest Analysis on RPRX</b></p><h2>Royalty Pharma Trading Down 1.0%</h2><ul><li>1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data</li></ul><p>Royalty Pharma stock opened at $52.85 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. Royalty Pharma has a one year low of $32.15 and a one year high of $53.47. The stock has a market capitalization of $30.43 billion, a PE ratio of 35.95, a price-to-earnings-growth ratio of 1.47 and a beta of 0.40. The business's fifty day moving average is $48.31 and its 200 day moving average is $43.35. </p><p>Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts' consensus estimates of $1.22 by $0.08. The business had revenue of $631.00 million during the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. On average, sell-side analysts predict that  Royalty Pharma will post 5.05 EPS for the current year. </p><h2>Royalty Pharma Dividend Announcement</h2><ul><li>4 Healthcare Stocks With Massive Gains—and More to Come</li></ul><p>The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Friday, May 15th. Royalty Pharma's dividend payout ratio  is 63.95%. </p><h2>Insider Buying and Selling at Royalty Pharma</h2><p>In related news, Director Gregory Norden sold 3,045 shares of the business's stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $53.00, for a total transaction of $161,385.00. Following the completion of the sale, the director directly owned 191,803 shares in the company, valued at approximately $10,165,559. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of the business's stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total transaction of $1,731,895.98. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 155,893 shares of company stock worth $7,512,360 in the last three months. 18.84% of the stock is currently owned by company insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors and hedge funds have recently modified their holdings of the business. LM Advisors LLC purchased a new stake in shares of  Royalty Pharma in the 4th quarter worth $26,000.  Lloyd Advisory Services LLC. bought a new stake in  Royalty Pharma during the fourth quarter valued at about $30,000.  Smartleaf Asset Management LLC grew its holdings in  Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 790 shares during the period.  Private Trust Co. NA increased its position in  Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 288 shares in the last quarter.  Finally, Blue Trust Inc. raised its stake in shares of  Royalty Pharma by 173.4% in the first quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 437 shares during the period. Hedge funds and other institutional investors own  54.35% of the company's stock. </p><h2>Royalty Pharma Company Profile</h2> (Get Free Report)<p>Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.  </p><p>The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Royalty Pharma</li><li>Peloton Stock Gives Back Gains After Upbeat Earnings Report</li><li>MarketBeat Week in Review – 05/11 - 05/15</li><li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li><li>Datavalut Gains Traction: 5 Reasons to Sell Now</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Royalty Pharma Right Now?</h2><p>Before you consider Royalty Pharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.</p><p>While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RPRX

<p>Royalty Pharma PLC (NASDAQ:RPRX) has received a consensus 'Buy' rating from seven brokerages. Analysts have set an average 1-year target price of $53.71. Recent upgrades include Morgan Stanley raising their target from $61 to $63 and Citigroup from $50 to $66. The company reported $1.30 EPS, exceeding estimates, and announced a quarterly dividend of $0.235 per share. Insider selling has occurred, with significant shares sold by Director Gregory Norden and CFO Terrance P. Coyne.</p>

Market Beat

Royalty Pharma PLC - CL

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

SPDR S&P Biotech

VG Health

iShares US Pharma

Health Care Select Sector SPDR

Morgan Stanley

Citigroup

Goldman Sachs

Zenas Biopharma

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GS Hldg R

Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Analysts